Skinvisible granted Japanese patent for Invisicare

NewsGuard 100/100 Score

Skinvisible, Inc. has announced that it has been granted a comprehensive patent in Japan for Invisicare, a product-enhancing polymer delivery system for topical dermatology products. The patent protects Invisicare in the areas of 'Topical Composition,' 'Topical Composition Precursor,' and 'Methods for Manufacturing and Using.'

Skinvisible's strong intellectual property protection is often the key catalyst for a company to license products formulated with Invisicare. Skinvisible's patents provide a guaranteed period of market exclusivity to licensees. Along with developing its own formulations, Skinvisible's research and development team works directly with companies offering life cycle management for their products coming off patent. Additionally, Invisicare offers unique attributes to topical products including the ability to hold active ingredients on the skin for extended periods of time and providing a controlled, fast or slow release of the active ingredient.

"Skinvisible continues to invest into patent protection for Invisicare and its unique characteristics," said Mr. Terry Howlett, President and CEO of Skinvisible. "The strength of our patents is paramount in the success of our product licensing strategy as pharmaceutical companies worldwide battle strong competition for their own products coming off patent. Along with a new patent, Invisicare provides an exciting new marketing story for companies to utilize."

In addition to this new patent approval for Japan, Skinvisible holds patent protection in the United States, Australia and India and has numerous US and international product patents pending.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers develop new way to make vegan food more appetizing